GBT

Voxelotor

Transcranial droppler (TCD) in SCD

Stage (next event)

Expected Date

Phase 3 post-approval confirmatory study Readout

December 5-8, 2021

Catalyst Info & Data Links

TITLE: Voxelotor for Transcranial droppler (TCD) in SCD post-approval confirmatory study Readout

  • Clinical Trial (NCT03036813) Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) 


WHAT IS THE NEXT CATALYST EVENT?

  • post-approval confirmatory study Readout


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 5-8, 2020


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION

  • Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, Oxbryta inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD. On November 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and older.9 As a condition of accelerated approval, GBT will continue to study voxelotor in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of Oxbryta to decrease stroke risk in children 2 to 15 years of age.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Lots of Uncertainty in Upcoming GLYC Sickle Cell Readout

Amp Core Q2 '19 Report

Amp Mid-Q1 '19 Update

Upcoming Catalysts On The Radar: ARQL & GBT

GBT's Part A Phase 3 Sickle Cell Data - Any Day Now

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon